

## GYNECOLOGIC ONCOLOGY FELLOWS AND FACULTY PRESENTATIONS AND PUBLICATIONS

### FELLOWS' PRESENTATIONS

#### **Presentations at regional or national meetings by fellows for the past 5 years:**

Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Muller CY, Miller DS, Schorge JO. Is Staging of Ovarian LMP Tumors Worth the Effort? A Multicenter Study of 229 Patients. Society of Gynecologic Oncologists' 35<sup>th</sup> Annual Meeting, San Diego, CA. February 2004.

Rao GG, Coleman RL, Rogers P, Nguyen P. Phase I Clinical Trial of Weekly Paclitaxel, Weekly Carboplatin and Concurrent Radiotherapy for Locally Advanced Cervical Cancer. Society of Gynecologic Oncologists' 35<sup>th</sup> Annual Meeting, San Diego, CA. February 2004.

Drake RD, Lee H, Rajanbabu R, Kim J-H, Miller DS, Mok SC, Schorge JO. Evaluation of Plasma Osteopontin in Diagnosing and Monitoring Ovarian Cancer. Society of Gynecologic Oncologists' 35<sup>th</sup> Annual Meeting, San Diego, CA. February 2004.

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Minna JD, Schorge JO. Restoration of Slit-2 Function: A Novel Therapeutic Option for Ovarian Cancer? Society of Gynecologic Oncologists' 35<sup>th</sup> Annual Meeting, San Diego, CA. February 2004.

Drake RD, Kim J, Mok SC, Schorge JO. Evaluation of plasma osteopontin in diagnosing and monitoring ovarian cancer. Oral presentation. Glaxo SmithKline 8<sup>th</sup> Annual National Gynecologic Oncology Fellows' Forum, San Diego, California. February 2004.

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Schorge JO. Restoration of Slit-2 function: a novel therapeutic option for ovarian cancer? Oral presentation. Glaxo SmithKline 8<sup>th</sup> Annual National Gynecologic Oncology Fellows' Forum, San Diego, California. February 2004.

Rao GG, Kurien A, Gossett D, Griffith WF, Muller CY. A Case-Control Study of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms in Cervical Carcinogenesis. AACR 95<sup>th</sup> Annual Meeting. Orlando, FL. March 2004.

Drake RD, Girard L, Lam DL, Minna JD, Schorge JO. Gene Expression Profiling to Predict Platinum-Sensitivity in Ovarian Cancer. AACR 95<sup>th</sup> Annual Meeting. Orlando, FL. March 2004.

Drake RD, Rao GG, Schorge JO. Gestational trophoblastic disease among Hispanic women: a 20-year experience at Parkland Memorial Hospital. New England Association of Gynecologic Oncologists 24<sup>th</sup> Annual Meeting, Chatham, MA. June 2004.

Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Fertility-sparing surgery for ovarian tumors of low malignant potential: a multicenter analysis. ACOG District VII Annual Meeting, Washington, D.C. October 2004

Drake RD, Rao GG, Schorge JO. Gestational trophoblastic disease among Hispanic women: a 20-year experience at Parkland Memorial Hospital. ACOG District VII Annual Meeting, Washington, D.C. October 2004.

Heffernan T, Giannios N, Jenison E. Malignant transformation in a case of chemotherapeutic retroconversion of immature ovarian teratoma. Poster presentation at AMA-RFS Research Symposium, Atlanta, GA. December 2004.

Drake RD, Girard L, Lam DL, Minna JD, Schorge JO. Gene expression profiling to predict platinum-sensitivity in ovarian cancer. 9<sup>th</sup> Annual National Gynecologic Oncology Fellows' Forum, Tuscon, Arizona. January 2005.

Bull SL, Schorge JO, Peyton MJ, Miller DS, Lea JS. Lack of mutations within the EGFR tyrosine kinase domain suggests resistance to gefitinib in ovarian cancer cells. Glaxo SmithKline 9<sup>th</sup> Annual National Gynecologic Oncology Fellows' Forum, Tuscon, Arizona. January 2005.

Knowles LM, Nandi A, Gurnani P, Miller DS, Mok S, Rosenblatt K, Schorge JO. Serum proteomic profiling to predict early relapse in ovarian cancer. Society of Gynecologic Oncologists' 36<sup>th</sup> Annual Meeting, Miami Beach, FL. March 2005.

Bull SL. Schorge JO, Peyton MJ, Miller DS, Lea JS. Lack of mutations within the EGFR tyrosine kinase domain suggests resistance to gefitinib in ovarian cancer cells. Society of Gynecologic Oncologist 36<sup>th</sup> Annual Meeting, Miami Beach, FL. March 2005.

Knowles LR, Drake RD, Ashfaq R, Miller DS, Schorge JO. Simplifying the diagnostic workup of molar pregnancy. American College of Obstetricians and Gynecologists 53<sup>rd</sup> Annual Meeting, San Francisco, CA. May 2005

Drake RD, Rao GG, Schorge JO. The incidence of GTD in Hispanic women: a 20-year experience at Parkland Memorial Hospital. American College of Obstetricians and Gynecologists 53<sup>rd</sup> Annual Meeting, San Francisco, CA. May 2005.

Martino MA, Elahi A, Sutphen R, Klippel C, Boren T, Dressman HK, Berchuck A. Expression analysis of genes involved in ovarian cancer metastasis. ASCO Annual Meeting, Orlando, FL. May 2005.

Bull SL, Garner EI, Walsh C, Gehrig PA, Schorge JO. Fertility-sparing surgery for 102 patients with cervical adenocarcinoma in situ. Society of Gynecologic Oncologists 37<sup>th</sup> Annual Meeting, Palm Springs, CA. March 2006.

Heffernan T, Kalahasti G, Muneer S, Castro-Rivera E, Schorge J, Miller D, Brekken R, Lea J. Secreted protein acidic and rich in cysteine (SPARC) may predict cervical cancer and modulate resistance to cytotoxic chemotherapy. Poster presentation, Society of Gynecologic Oncologists Annual Meeting, Palm Springs CA. March 2006.

Purinton SC, Santillan A, Diaz-Montes TP, Giuntoli II RL, Gardner GJ, Bristow RE. Cost-effectiveness of routine cytology for endometrial cancer surveillance. Society of Gynecologic Oncologists 37<sup>th</sup> Annual Meeting, Palm Springs, CA. March 2006.

Heffernan TP, Minna JD, Miller DS, Schorge JO, Lea JS. Loss of secreted protein rich and acidic in cysteine (SPARC) may predict cervical carcinogenesis and modulate resistance to cytotoxic chemotherapy. Society of Gynecologic Oncologists 37<sup>th</sup> Annual Meeting, Palm Springs, CA. March 2006.

Bull SL, Garner EI, Walsh CS, Gehrig PA, Schorge JO. Fertility-sparing surgery for 101 patients with cervical adenocarcinoma in situ. Society of Gynecologic Oncologists 37<sup>th</sup> Annual Meeting on Women's Cancer, Palm Springs, CA. March 2006. Poster Presentation.

Bull SL, Garner EI, Walsh C, Gehrig PA, Schorge JO. Is it worth the risk to preserve fertility in cervical adenocarcinoma in situ? Western Association of Gynecologic Oncologists 35<sup>th</sup> Annual Meeting, Lake Tahoe, CA. May 2006.

Bull SL, Schorge JO, Peyton MJ, Xiang L, Miller DS, Minna JD, Lea JS. Implications of HER family inhibition in targeted therapy of ovarian cancer. 2006 Annual Meeting of the American Society of Clinical Oncology, Abstract 13120. *Journal of Clinical Oncology*. Vol 24, No 18S; Part 1. 611s, 2006.

Lea JS, Kalahasti G, Peyton MJ, Bull SL, Miller DS, Minna JD. Targeted inhibition of EGFR alone in cervical cancers may not produce a clinical response. Society of Gynecologic Oncologists 37<sup>th</sup> Annual Meeting on Women's Cancer, Palm Springs, California. Poster Presentation. 2006

Bull SL, Castro-Rivera E, Miller DS, Brekken RA, Lea JS. Modulation of SPARC as a novel therapeutic option for platinum-resistant ovarian cancer cell lines. Western Association of Gynecologic Oncologists 35<sup>th</sup> Annual Meeting, Lake Tahoe, CA. May 2006.

Bull SL, Carbon JG, Miller AF, Miller DS, Brekken RA, Lea JS. SPARC modulation decreases tumor growth and confers chemosensitivity in platinum-resistant ovarian cancer. 38<sup>th</sup> Annual Meeting of the Society of Gynecologic Oncologists. March 2007.

Phelps SLB, Wingo SN, Schorge JO, Miller DS. What number of lymph nodes should be removed in early stage endometrial cancer? 2007 District VII Annual Meeting of the American College of Obstetricians and Gynecologists. Henderson, NV. October 2007. George Schneider Award for Oral Presentation by a Junior Fellow.

Bull SL, Carbon JG, Miller AF, Castro-Rivera E, Arnold S, Miller DS, Brekken RA and Lea JS. SPARC modulation decreases tumor growth and confers chemosensitivity in platinum-resistant ovarian cancer. Society of Gynecologic Oncologists 38th Annual Meeting on Women's Cancer, San Diego, CA. March 2007. Poster presentation.

Wingo SN, Elmore RG, Miller DS, Raheela A, Lea JS. An immunohistochemical evaluation of vascular endothelial growth factor, urokinase-type plasminogen activator, and microvessel density in normal, preinvasive, and invasive lesions of the cervix. March 2007.

Boren T, Dressman HK, Cui S, Chan G, Lancaster J. MicroRNAs that underlie response to salvage chemotherapy in ovarian cancer. ASCO Annual Meeting, Chicago, IL. June 2007.

Heffernan T, Kalahasti G, Muneer S, Castro-Rivera E, Schorge J, Miller D, Brekken R, Lea J. Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a Predictor of Cervical Carcinogenesis and Regulator of Cervical Cancer Growth. Plenary Session. 36<sup>th</sup> Annual Meeting of Western Association of Gynecologic Oncology, Sun River, OR. June 2007.

Boren T, Phelan C, Huang Y, Liebow M, Federicksen Z, Pankratz V, Goode E, Olsen J, Vierkant R, Cunningham J, Schildkrout J, Sellers T, Lancaster J. Genomic analysis of ovarian cancers can identify single nucleotide polymorphisms associated with ovarian cancer risk. Received "Scholar-In-Training" award. AACR Annual Meeting, Los Angeles, CA. April 2007.

Phelps SLB, Wingo SN, Schorge JO, Miller DS. What number of lymph nodes should be removed in early stage endometrial cancer? 2007 District VII Annual Meeting of the American College of Obstetricians and Gynecologists. Henderson, NV. George Schneider Award.

Bull SL, Carbon JG, Miller AF, Castro-Rivera E, Arnold S, Miller DS, Brekken RA and Lea JS. SPARC modulation decreases tumor growth and confers chemosensitivity in platinum-resistant ovarian cancer. *Gynecologic Oncology*; 104: 3,1; S43, March 2007.

Cui S, Boren T, Chan C, Indermaur M, Dressman HK, Lancaster J. MicroRNAs that underlie ovarian cancer development and response to chemotherapy. AACR Annual Meeting, Los Angeles, CA. April 2007.

Indermaur M, Boren T, Cui S, Chan G, Kressman HK, Lancaster JM. MicroRNA profiles associated with endometrial cancer development and response to Cisplatin and Doxorubicin chemotherapy. Society of Gynecologic Oncologists Annual Meeting, Tampa, FL. March 2007.

Indermaur M, Dressman HK, Chan G, Boren T, Cui S, Risinger J, Maxwell L, Berchuck A, Lancaster J. Gene networks that determine endometrial cancer chemo-response. Society of Gynecologic Oncologists Annual Meeting, Tampa, FL. March 2007.

Wingo SN, Elmore RG, Miller DS, Ashfaq R, Lea JS. An immunohistochemical evaluation of VEGF C, uPA, and microvessel density in normal, preinvasive, and invasive lesions of the cervix. Poster. Society of Gynecologic Oncologist 38<sup>th</sup> Annual Meeting, San Diego, CA. March 2007.

Wingo SN, Elmore RG, Miller DS, Ashfaq R, Lea JS. An immunohistochemical evaluation of VEGF C, uPA, and microvessel density in normal, preinvasive, and invasive lesions of the cervix. Poster. Harold C. Simmons Comprehensive Cancer Center 2<sup>nd</sup> Annual Scientific Retreat Poster Presentation, Dallas, TX. April 2007.

Phelps SLB, Wingo SN, Schorge JO, Miller DS. What number of lymph nodes should be removed in early stage endometrial cancer? 2007 District VII Annual Meeting of the American College of Obstetricians and Gynecologists., Henderson, NV. October 2007. George Schneider Award.

Indermaur MD, Boren T, Cragun J, Wenham R, Apte S, Chan G, Kamath SG, Wei H, Dressman HK, Lancaster JM. Formalin-fixed, paraffin-embedded ovarian cancer gene expression signatures associated with platinum response. Society of Gynecologic Oncologist Annual Meeting, Tampa, FL. March 2008.

Boren T, Dressman HK, Kamath S, Wei ZZ, Cragun J, Humphrey M, Chen N, Xiong Y, Lancaster JM. MicroRNAs and their target messenger RNAs associated with the development of endometrial carcinoma. Society of Gynecologic Oncologist Annual Meeting, Tampa, FL. March 2008.

Boren T, Dressman HK, Wei ZZ, Martino A, Zhang T, Palmer J, Lancaster JM. Gene expression patterns in formalin-fixed, paraffin-embedded endometrial tissue associated with lymph node metastasis. Society of Gynecologic Oncologist Annual Meeting, Tampa, FL. March 2008.

Contreras CM, Gurumurthy S, Haynie JM, Shirley L, Akbay E, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Catrillon DH. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Poster. Harold C. Simmons Comprehensive Cancer Center 3<sup>rd</sup> Annual Scientific Retreat Poster Presentation, Dallas, TX, March 2008.

Lacour RA, Westin SN, Daniels MS, Meyer LA, Coubey VC, Blank SV, MacDonald, HR, Roman LR, Estes JM, Barnes M, Teoh D, Powell BA, Wingo SN, Schorge JO, Brooks R, Mutch D, Babb S, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-stage ovarian cancer? Society of Gynecologic Oncologist 39<sup>th</sup> Annual Meeting, San Diego, CA, March 2008.

Contreras CM, Gurumurthy S, Haynie JM, Shirley L, Akbay E, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Poster American Association for Cancer Research, San Diego, CA, April 2008.

Schorge JO, Drake RD, Wingo SN, Purinton SC, Xie Y. Gene expression profiling to predict early relapse in ovarian cancer: a strategy for personalizing therapy? New England Association of Gynecologic Oncologists Meeting, June 2008.

Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum sensitive ovarian cancer. New England Association of Gynecologic Oncologist Meeting, June 2008.

Schorge, JO, Drake RD, Wingo SN, Purinton SC, Xie Y. Gene expression profiling to predict early relapse in ovarian cancer: a strategy for personalizing therapy. New England Association of Gynecologic Oncologist Meetin, June 2008.

Lacour RA, Westin SN, Daniels MS, Meyer LA, Coubey VC, Blank SV, MacDonald, HR, Roman LR, Estes JM, Barnes M, Teoh D, Powell BA, Wingo SN, Schorge JO, Brooks R, Mutch D, Babb S, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-stage ovarian cancer? Western Association of Gynecologic Oncologist Meeting, June 2008.

Heffernan TP, Arnold SA, Rivera L, Carbon J, Brekken RA, Miller DS, Lea JS. Forced SPARC overexpression results in increased tumor size and decreased necrosis in a murine human cervical cancer model. Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009.

Boren TP, Wingo, SN, Contreras CM, Akbay EA, Schidler MJ, Schorge JO, Miller DS, Castrillion DH. LKB1 promoter Methylation status in cervical and endometrial cancers. Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009

Schorge JO, Drake RD, Xiao G, Wingo, SN, Xie Y. Gene expression profiling to predict early relapse in ovarian cancer. Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009.

King L, Wingo S, Heffernan TP, Schorge JO. Intraperitoneal chemotherapy in stage II ovarian cancer: how many patients receive this “standard of care” treatment? Poster presentation at American College of Surgeons North Texas Chapter meeting, March 2009.

## FELLOWS' PUBLICATIONS

### **Publications involving fellows over the past 5 years**

#### **Abstracts:**

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Minna JD, Schorge JO. Restoration of Slit-2 function: a novel therapeutic option for ovarian cancer? *Gynecol Oncol* 2004 92:463.

Drake RD, Girard L, Lam DL, Minna JD, Schorge JO. Gene expression profiling to predict platinum-sensitivity in ovarian cancer. *Proc Am Assoc Cancer Res* 2004 45:518.

Rao GG, Kurien A, Gossett D, Griffith WF, Muller CY. A case-control study of methylenetetrahydrofolate reductase (MTHFR) polymorphisms in cervical carcinogenesis. *Proc Am Assoc Cancer Res* 2004 45:983.

Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Muller CY, Miller DS, Schorge JO. Is staging of ovarian LMP tumors worth the effort: a multicenter study of 229 patients. *Gynecol Oncol* 2004 92:415-6.

Rao G, Coleman RL, Rogers P, Nguyen P. Phase I clinical trial of weekly paclitaxel, weekly carboplatin and concurrent radiotherapy for locally advanced cervical cancer. *Gynecol Oncol* 2004 92:426.

Drake RD, Lee H, Rajanbabu R, Kim J, Miller DS, Mok SC, Schorge JO. Evaluation of plasma osteopontin in diagnosing and monitoring ovarian cancer. *Gynecol Oncol* 2004 92:462-3.

Knowles LM, Drake RD, Morrissey C, Rajanbabu R, Miller DS, Schorge JO. Restoration of Slit-2 function: a novel therapeutic option for ovarian cancer? *Gynecol Oncol* 2004 92:463.

Lavie I, Rao G, Drake R, Knowles L, Miller D, Schorge J. A reevaluation of hCG surveillance in partial hydatidiform moles. Joint Meeting of the Western Association of Gynecologic Oncologists and The Felix Rutledge Society, 62, 2004.

Knowles, L, Drake, R, Morrissey, C, Rajanbabu, R, Miller, D, Minna, J, Schorge, J. Restoration of SLIT-2 Function: A Novel Therapeutic Option for Ovarian Cancer. The 2004 GlaxoSmithKline National Gynecologic Oncology Fellow's Forum, 2004.

Williamson E, Martino MA, Hoffman MS, Boren T, Siegfried S, Roberts W, Cantor A, Fiorica J. The incidence of pulmonary embolism after gynecologic oncology surgery. *J Clin Oncol*. 2005 ASCO Annual Meeting Proceedings 23(16S):5089.

Knowles LM, Drake RD, Ashfaq R, Miller DS, Schorge JO. Simplifying the diagnostic workup of molar pregnancy. *Obstet Gynecol* 2005 105:118s.

Bull SL, Schorge JO, Peyton MJ, Xiang L, Miller DS, Lea JS. Lack of Mutations within the EGFR Tyrosine Kinase Domain Suggests Resistance to Gefitinib in Ovarian Cancer Cells. *Gynecologic Oncology*; 96: 1017-1018, 2005.

Drake RD, Rao GG, Schorge JO. The incidence of GTD in Hispanic women: a 20-year experience at Parkland Memorial Hospital. *Obstet Gynecol* 2005 105:119s.

Knowles LM, Nandi A, Gurnani P, Miller DS, Mok SC, Rosenblatt K, Schorge JO. Serum proteomic profiling to predict early relapse in ovarian cancer. *Gynecol Oncol* 2005 96:926.

Bull SL, Schorge JO, Peyton MJ, Miller DS, Lea JS. Lack of mutations within the EGFR tyrosine kinase domain suggests resistance to gefitinib in ovarian cancer cells. *Gynecol Oncol* 2005 96:1017-8.

Boren T, Martino MA, Williamson E, Twitty P, Siegfried S, Fiorica J. The cost of treating pulmonary embolisms following surgery for gynecological malignancies. *J Clin Oncol* 2005 ASCO Annual Meeting Proceedings 23(16S):8250

Bull SL, Garner EI, Walsh C, Gehrig PA, Schorge JO. Fertility-sparing surgery for 102 patients with cervical adenocarcinoma in situ. *Gynecol Oncol* 2006 101:s94.

Lea JS, Kalahasti G, Peyton MJ, Bull SL, Miller DS, Minna JD. Targeted inhibition of EGFR alone in cervical cancers may not produce a clinical response. *Gynecol Oncol* 2006 101:s133-4.

Bull SL, Garner EI, Walsh CS, Gehrig PA, Schorge JO. Fertility-sparing surgery for 102 women with cervical adenocarcinoma in situ. *Gynecologic Oncology* 2006 101:1,1; S94.

Bull SL, Schorge JO, Peyton MJ, Xiang L, Miller DS, Minna JD, Lea JS. Implications of HER family inhibition in targeted therapy of ovarian cancer. 2006 Annual Meeting of the American Society of Clinical Oncology, Abstract 13120. *Journal of Clinical Oncology* 2006 24(18S)(Part 1):611s.

Heffernan TP, Minna JD, Miller DS, Schorge JO, Lea JS. Loss of secreted protein rich and acidic in cysteine (SPARC) may predict cervical carcinogenesis and modulate resistance to cytotoxic chemotherapy. *Gynecol Oncol* 2006 (in press).

Bull SL, Schorge JO, Peyton MJ, Xiang L, Miller DS, Minna JD, Lea JS. Implications of HER family inhibition in targeted therapy of ovarian cancer. *Proc Am Soc Clin Oncol* 2006 (in press).

Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. *Am J Obstet Gynec* 2006 194(5): e20-2.

Bull SL, Carbon JG, Miller AF, Castro-Rivera E, Arnold S, Miller DS, Brekken RA and Lea JS. SPARC modulation decreases tumor growth and confers chemosensitivity in platinum-resistant ovarian cancer. *Gynecologic Oncology* 2007 104( 3,1):S43.

Contreras CM, Gurumurthy S, Haynie JM, Shirley L, Akbay E, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Catrillon DH. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. *Cancer Research*. 2008 68(3):759-66.

Schorge JO, Drake RD, Wingo SN, Purinton SC, Xie Y. Gene expression profiling to predict early relapse in ovarian cancer: a strategy for personalizing therapy? New England Association of Gynecologic Oncologists Meeting, June 13-15, 2008.

Heffernan TP, Arnold SA, Rivera L, Carbon J, Brekken RA, Miller DS, Lea JS. Forced SPARC overexpression results in increased tumor size and decreased necrosis in a murine human cervical cancer model. Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009. Gynecol Oncol 112(2) S2-S185, 2009.

Boren TP Wingo SN Contreras CM Akbay EA Schidler MJ Schorge JO Miller DS Castrillion DH LKB1 promoter methylation status in cervical and endometrial cancers Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009. Gynecol Oncol 112(2) S2-S185, 2009.

Schorge JO, Drake RD, Xiao G, Wingo SN, Xie Y. Gene expression profiling to predict early relapse in ovarian cancer. Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009. Gynecol Oncol 112(2) S2-S185, 2009

Cragum J, Xiong Y, Boren TP, Indermaur MD, Sayer R, Humphrey MM, Cottrill HM, Kamath S, Hakam A, Apte SM, Wenham RM, Berchuck A, Lancaster JM. GPR30 expression predicts chemotherapy responsiveness and overall and progression-free survival in patients with epithelial ovarian cancer. Society of Gynecologic Oncologists, 40<sup>th</sup> Annual Meeting, San Antonio, Texas, February 5-8, 2009. Gynecol Oncol 112(2) S2-S185, 2009.

### **Book Chapters:**

Schorge JO, Knowles LM, Lea JS. Adenocarcinoma of Cervix. Curr Treat Options Oncol 2004 5(2):119-227.

Schorge JO, Bull SL, Lea JS. Current management of in situ and invasive cervical adenocarcinoma. Curr Women's Health Rev 2005 1:185-96.

Purinton SC, Goldstein A. Female sexual function and dysfunction. The Johns Hopkins Manual of Gynecology and Obstetrics. Third Ed. Lippincott Williams & Wilkins. Chapter 38, 436-450, 2007.

Purinton, S.C. and A.Goldstein. Female sexual function and dysfunction. The Johns Hopkins Review of Gynecology and Obstetrics. Second Ed. Lippincott Williams & Wilkins. Chapter 38, 153-155, 2007.

Pavone ME, Purinton SC, Petersen S. Post-partum care and breast-feeding. The Johns Hopkins Manual of Gynecology and Obstetrics. Third Ed. Lippincott Williams & Wilkins. Chapter 20, 245-252, 2007.

Pavone ME, Purinton SC, Petersen S. Post-partum care and breast feeding. The Johns Hopkins Review of Gynecology and Obstetrics. Second Ed. Lippincott Williams & Wilkins. Chapter 20, 82-84, 2007.

Knowles LM, Schorge JO. Ovarian sex cord-stromal tumors. Handbook of Gynecologic Oncology, McGraw-Hill. 2007 (in press)

### **Peer-review Articles:**

Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller CY. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soc Gynecol Invest 2004 11:329-37.

Lea JS, Coleman RL, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 2004 190:674-9.

Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004 10:3474-8.

Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004 94:320-4.

Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 2004 104:261-6.

Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005 98:263-6.

Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. Am J Obstet Gynecol 2005 192:1362-4.

Li AJ, Giuntoli RL 2<sup>nd</sup>, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 2005 106:1304-8.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 2005;96:168-72.

Oh JH, Gao J, Nandi A, Gurnani P, Knowles L, Schorge J. Diagnosis of early relapse in ovarian cancer using serum proteomic profiling. Genome Inform 2005 16(2):195-204.

Bristow, RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL. Cost-effectiveness of routine cytology for endometrial cancer surveillance. Gynecol. Oncol 103(2), 709-713, 2006.

Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO. Retrospective cohort study of surgical staging for ovarian low malignant tumors. Am J Obstet Gynecol 2006 194:e20-22.

Drake RD, Rao GG, McIntire DD, Miller DS, Schorge JO. Gestational trophoblastic disease among Hispanic women: a 21-year hospital-based study. Gynecol Oncol 2006 103(1):81-86.

Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO. Simplifying the pre-evacuation testing strategy for patients with molar pregnancy. J Reprod Med. 2006 52(8):685-688.

Wingo SN, Knowles LM, Carrick KS, Miller, DS, Schorge JO. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. Am J Obstet Gynecol. 2006 194(5):20-2.

Oh J, Nandi A, Gurnani P, Knowles L, Schorge JO, Rosenblatt, KP, Gao, JX. Proteomic biomarker identification for diagnosis of early relapse in ovary cancer. J Bioinform Comput Biol. 2006 4(6):1159-79.

Boren T, LaPolla J, Martino MA, Nirgudkar P. Aggressive angiomyxoma: a case of multiple recurrences and review of the literature. J Pelvic Med Surg 2006 12(4):151-156.

Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO. Fertility-Sparing Surgery in 101 Women with Adenocarcinoma in Situ of the Cervix. Gynecologic Oncology 2007 107(2):316-9.

Boren T, Reyes C, Montenegro R, Raimer K. A case of Evan's syndrome in pregnancy refractory to primary treatment options. J Matern Fetal Neonatal Med 2007 20(11):843-5.

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecologic Oncology 2008 110(2):206-15.

Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang L, Miller DS, Lea JS. Implications of EGFR Inhibition in Ovarian Cancer Cell Proliferation. Gynecologic Oncology 2008 109(3):411-7.

Bull SL, Carbon JG, Miller AF, Castro-Rivera E, Arnold S, Miller DS, Brekken RA and Lea JS. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol. 2008 Nov 5. [Epub ahead of print] Pubmed ID: 18992864.

Contreras CM, Gurumurthy S, Haynie JM, Shirley L, Akbay E, Wingo SN, Schorge JO, Broadus RR, Wong KK, Bardeesy N, Castrillon DH. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Research. 2008 Feb 1;68(3):759-66.

Berchuk A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009 Apr 1;15(7):2448-55 Epub 2009 Mar 24

Wingo, SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH. Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE. 2009;4(4):e5137. Epub Apr 2.

## FACULTY PUBLICATIONS

### **Articles by program faculty published in peer-review journals during the last 5 years:**

Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A. Evaluation of Vinorelbine in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:639-43.

Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859-68.

Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004;94:320-4.

Moller KA, Gehrig PA, Van Le L, Secord AA, Schorge J. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 2004;94:170-4.

Muller CY, Schorge JO, Tomlinson GE, Ashfaq R. BRCA Pap? Feasibility of clinical BRCA testing on liquid-based cervical cytology: implications for biomarker development. Cancer Epidemiol Biomarkers Prev 2004;13:1534-7.

Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 2004;104:261-6.

Delin JB, Miller DS, Coleman RL. Other Primary Malignancies in Patients with Uterine Corpus Malignancy. Am J Obstet Gynecol 2004;190:1429-31.

Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller CY. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soc Gynecol Invest 2004;11:329-37.

Lea JS, Kurien A, Schorge JO, Coleman RL, Miller DS, Muller CY. Aberrant p16 methylation in squamous cell cervical cancers and high grade squamous dysplasia is a potential biomarker of tobacco induced DNA damage. Am J Obstet Gynecol 2004;190:674-9.

Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R. p16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 2004;190:668-73.

Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004;10:3474-8.

Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Brenda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:3113-9.

Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;96:67-71.

Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;96:810-7.

Long HJ, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Randomized phase III trial of Cisplatin with or without Topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:4626-33.

Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:217-21.

Li AJ, Giuntoli RL, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 2005;106:1304-8.

Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005;98:263-6.

Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. Am J Obstet Gynecol 2005;192:1362-4.

Lacour RA, Garner EO, Molpus KL, Ashfaq R, Schorge JO. Management of cervical adenocarcinoma in situ during pregnancy. *Am J Obstet Gynecol* 2005;192:1449-51.

Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO. Promoter hypermethylation profile of ovarian epithelial neoplasms. *Clin Cancer Res* 2005;11:5365-9.

Rao GG, Miller DS. Clinical applications of hormonal therapy in ovarian cancer. *Curr Treat Options Oncol* 2005;6(2):97-102.

Long JH, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Randomized phase III clinical trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *J Clin Oncol* 2005; 23(21):4626-33.

Bull SL, Schorge JS, Peyton MJ, Xiang L, Miller DS, Lea JS. Lack of mutations within the EGFR tyrosine kinase domain suggests resistance to gefitinib in ovarian cancer cells. *Gynecol Oncol* 2005; 96:1017-1018.

Ferguson DA, Muenster MR, Zang Q, Spencer JA, Schageman JJ, Lian Y, Garner HR, Gaynor RB, Huff JW, Pertsemelidis A, Schorge J, Becerra C, Williams NS, Graff JM. CAST, a rapid method to identify cell-surface and secreted proteins: a large scale screen for breast and ovarian cancer markers. *Cancer Res* 2005;65:8209-17.

Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. *Clin Cancer Res* 2005;11:7651-7.

Oh JH, Gao J, Nandi A, Gurnani P, Knowles L, Schorge J. Diagnosis of early relapse in ovarian cancer using serum proteomic profiling. *Genome Inform* 2005;16:195-204.

Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. *Expert Rev Anticancer Ther* 2006;6:43-47.

Lea JS, Kalahasti G, Peyton MJ, Bull SL, Miller DS, Minna JD. Targeted inhibition of EGFR alone in cervical cancers may not produce a clinical response. *Gynecol Oncol* 2006; 101:1,1:S133-134.

Miller DS. Advanced endometrial cancer: is lymphadenectomy necessary or sufficient? *Gynecol Oncol* 2006;101(2):191-93.

Long HJ, Monk BJ, Huang HQ, Grendys EC Jr., McMeekin DS, Sorosky J, Miller DS, Eaton LS, Fiorica JV. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. *Gynecol Oncol* 2006;100:537-43.

Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO. Retrospective cohort study of surgical staging for ovarian low malignant tumors. *Am J Obstet Gynecol* 2006;194:e20-22.

Drake RD, Rao GG, McIntire DD, Miller DS, Schorge JO. Gestational trophoblastic disease among Hispanic women: a 21-year hospital-based study. *Gynecol Oncol* 2006; 103(1):81-86.

Oh JH, Nandi A, Gurnani P, Knowles L, Schorge J, Rosenblatt KP, Gao JX. Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. *J Bioinform Comput Biol* 2006 4(6):1159-79.

Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO. Simplifying the pre-evacuation testing strategy for patients with molar pregnancy. *J Reprod Med* 2007 52(8):685-8.

Lea JS, Sunaga N, Sato M, Kalahasti G, Burbee DG, Minna JD, Muller CY. Silencing of HPV 18 oncoproteins with RNA Interference causes growth inhibition of cervical cancer cells. *Reprod Sci* 2007 14(1):20-8.

Bull SL, Carbon JG, Miller AF, Castro-Rivera E, Arnold S, Miller DS, Brekken RA, and Lea JS. SPARC modulation decreases tumor growth and confers chemosensitivity in platinum-resistant ovarian cancer. *Gynecol Oncol* 2007;104:3,1;S43.

Bull Phelps SL, Garner EL, Walsh CS, Gehrig PA, Miller DS, Schorge JO. Simplifying the preevacuation testing strategy for patients with molar pregnancy. *R Reprod Med* 2007;52(8):685-8.

Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson Dm, Broaddus RR. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. *J Clin Oncol* 2007;25(33):5158-64.

Bull Phelps SL, Garner EL, Walsh CS, Gehrig PA, Miller DS, Schorge JO. Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. *Gynecol Oncol* 2007;107(2):316-9.

Phelps SLB, Schorge SO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS. Implications of EGFR inhibition in ovarian cancer cell proliferation. *Gynecol Oncol* 2008;109(3):411-17.

Miller DS, Blessings JA, Bodurka DC, Bonebrake AJ, Schorge JO. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. *Gynecol Oncol* 2008;110(1):65-70.

Akbay EA, Contreras CM, Perera SA, Sullivan JP, Broaddus RR, Schorge JO, Ashfaq R, Saorian H, Wong KK, Castrillon DH. Differential roles of telomere attrition in type I and II endometrial carcinogenesis. *Am J Pathol* 2008;173(2):536-44.

Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC: Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008;14(3):764-71.

Contreras CM, Gurumurthy S, Haynie Jm, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH: Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008;68(3):759-66.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RI, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359(25):2641-2650.

Akbay EA, Contreras CM, Perera SA, Sullivan JP, Broaddus RR, Schorge JO, Ashfaq R, Saboorian H, Wong KK, Castrillon DH. Differential roles of telomere attrition in type I and II endometrial carcinogenesis. Am J Pathol 2008;173(2):536-44.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2008, Sept 24.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennings NB, Kinch MS, Tice M, Sood Ak. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 2008 10(11):1259-67.

Miller DS, King LP. Gynecologic oncology group trials in uterine corpus malignancies: recent progress. J Gynecol Oncol 19(4):218-222, 2008

Wingo, SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH. Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 4(4):e5137, 2009

Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol 27(16):2686-91, 2009

Miller DS, Fleming G, Randall ME. Chemo-and radiotherapy in adjuvant management of optimally debulked endometrial cancer. JNCCN 7(5):535-541, 2009

King LP, Miller DS. Recent progress: Gynecology Oncology Group trials in uterine corpus tumors. Rev Recent Clin Trials 4(2):70-4, 2009

Medel NI, Bansal S, Miller DS, Wright JD, Herzog, TJ. Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother 10(12):1939-51, 2009